Related Experiment Videos
Autolysis of methicillin-resistant Staphylococcus aureus is involved in synergism between imipenem and cefotiam
K Matsuda1, K Nakamura, Y Adachi
1Department of Molecular Biology, School of Medicine, Kitasato University, Tokyo, Japan.
Abstract:
Imipenem-induced autolysis and the activity of imipenem plus cefotiam were studied in 16 strains of methicillin-resistant Staphylococcus aureus (MRSA). The degree of imipenem-induced autolysis and the rate of synergistic action of imipenem plus cefotiam varied among strains and did not correlate with susceptibility to either imipenem or cefotiam. However, the degree of autolysis correlated well with susceptibility to the synergistic action of imipenem plus cefotiam. In methicillin-susceptible S. aureus strains, both imipenem-induced autolysis and the synergistic activity of the combined drugs were less than those observed in MRSA strains. Differences in the degree of autolysis were not due to differences in autolytic enzyme production. The autolysis of imipenem-pretreated MRSA was enhanced further by cefotiam, while treatment of cells in the reverse order did not enhance autolysis. These findings indicate that cell wall impairment in MRSA is caused by exposure to imipenem but not to cefotiam and that this difference in drug actions results in synergism between imipenem and cefotiam. The possible participation of penicillin-binding proteins PBP 2' and PBP4 in the observed effect is discussed.
Insights
Imipenem triggers autolysis (cell wall breakdown) in methicillin-resistant Staphylococcus aureus (MRSA), enhancing cefotiam
Area of Science:
- Microbiology
- Antibiotic Resistance
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to its resistance to common antibiotics.
- Understanding the mechanisms of antibiotic action and synergy is crucial for developing effective treatment strategies against MRSA.
Purpose of the Study:
- To investigate the autolytic response of MRSA to imipenem and the synergistic activity of imipenem combined with cefotiam.
- To explore the relationship between imipenem-induced autolysis and the synergistic efficacy of the drug combination.
Main Methods:
- Studied 16 MRSA strains and methicillin-susceptible S. aureus (MSSA) strains.
- Assessed imipenem-induced autolysis and the synergistic activity of imipenem plus cefotiam.
- Investigated the order of drug administration (imipenem then cefotiam vs. cefotiam then imipenem).
Main Results:
- Imipenem-induced autolysis and drug synergy varied among MRSA strains, correlating with autolysis but not direct susceptibility.
- MRSA strains exhibited greater autolysis and synergy compared to MSSA strains.
- Cefotiam enhanced imipenem-pretreated MRSA autolysis, but not vice versa, indicating imipenem's role in cell wall impairment.
Conclusions:
- Imipenem, not cefotiam, causes cell wall impairment in MRSA, leading to synergistic effects when combined.
- The degree of autolysis is a key factor predicting the synergistic activity of imipenem and cefotiam against MRSA.
- Penicillin-binding proteins PBP 2' and PBP4 may play a role in these observed effects.